AUPH - Aurinia Pharmaceuticals Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.77
-0.09 (-1.54%)
At close: 4:00PM EDT

5.77 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close5.86
Open5.86
Bid5.75 x 1800
Ask5.81 x 1300
Day's Range5.74 - 5.97
52 Week Range5.06 - 7.85
Volume413,578
Avg. Volume448,443
Market Cap528.399M
Beta (3Y Monthly)-0.17
PE Ratio (TTM)N/A
EPS (TTM)-0.70
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.92
Trade prices are not sourced from all markets
  • TheStreet.com

    An Example of How I Stalk a Trade

    Although I trade in a variety of time frames, the trades that produce the best returns are those that develop over the course of weeks or months. The strategy I use can be applied over a shorter time frame but typically if you are looking to play news flow it will require some patience.

  • Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Lags Revenue Estimates
    Zacks

    Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Lags Revenue Estimates

    Aurinia (AUPH) delivered earnings and revenue surprises of -13.33% and -45.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Aurinia Reports Second Quarter 2019 Financial Results and Operational Highlights

    - Fully-enrolled AURORA Phase 3 trial in lupus nephritis continues on track with results anticipated in late 2019 –

  • Will Aurinia Pharmaceuticals (AUPH) Report Negative Q2 Earnings? What You Should Know
    Zacks

    Will Aurinia Pharmaceuticals (AUPH) Report Negative Q2 Earnings? What You Should Know

    Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • MoneyShow

    Aurinia- From Dry Eye to Lupus Nephritis

    Aurinia Pharmaceuticals (AUPH) is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet need, explains small cap expert Tom Bishop, editor of BI Research.

  • Business Wire

    Aurinia Announces Further Strengthening of the Senior Management Team

    Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP) (the “Company”), a late-stage clinical biopharmaceutical company with ongoing research in lupus nephritis (“LN”), today announced the appointments of Mr. Max Donley as Executive Vice President of Internal Operations and Strategy and Dr. Glenn Schulman as Senior Vice President of Corporate Communications and Investor Relations.

  • Business Wire

    ILJIN Comments on Aurinia Pharmaceutical’s Annual Meeting

    ILJIN SNT Co., Ltd. , a founding shareholder of Aurinia Pharmaceuticals Inc. , which together with certain affiliates holds an approximate 14% ownership interest in Aurinia, today commented on the voting results of the Aurinia annual meeting of shareholders.

  • Business Wire

    Aurinia Shareholders Elect all Eight Directors at 2019 Annual General Meeting

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) is pleased to announce that shareholders of the Company (the “Shareholders”) elected all eight of the Company’s highly qualified director nominees at the Company’s Annual General Meeting held on June 26, 2019 (the “Meeting”).

  • Business Wire

    ILJIN Chairman Issues Open Letter to Aurinia Shareholders

    ILJIN SNT Co., Ltd. (“ILJIN”), a founding shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH, TSX: AUP) (“Aurinia” or the “Corporation”), which together with certain affiliates holds an approximate 14% ownership interest in Aurinia, today issued an open letter to Aurinia shareholders from ILJIN Group Chairman, Mr. Chin Kyu Huh. On June 3, 2019, we, ILJIN SNT Co., Ltd. and its affiliated companies (collectively, the “ILJIN Group”), filed an information circular (the "Circular") seeking to replace three incumbent directors with more capable and independent directors at the upcoming Annual General Meeting of Shareholders of Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) to be held on June 26, 2019.

  • Business Wire

    Aurinia Reminds Shareholders to Vote the YELLOW Proxy Prior to June 24 Deadline

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today reminded shareholders to vote in advance of the proxy voting deadline of 10:00 AM Mountain Time on Monday, June 24, 2019. Aurinia urges shareholders to vote the YELLOW proxy in support of management’s nominees. Aurinia’s Chairman, Dr. George M. Milne, Jr. said: “We are grateful for the support we have received and encourage shareholders to vote the YELLOW proxy today.

  • Business Wire

    As Deadline Approaches ILJIN SNT Reminds Aurinia Shareholders to Vote the GREEN Proxy for Nominees Committed to Correcting Governance Failures and to Realizing Aurinia’s Full Potential

    ILJIN SNT Co., Ltd. (“ILJIN”), a founding shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH, TSX: AUP) (“Aurinia” or the “Corporation”), which together with certain affiliates holds an approximate 14% ownership interest in Aurinia, today thanks shareholders for their support ahead of the upcoming Annual General Meeting of Shareholders and encourages all shareholders who haven’t yet voted to vote their GREEN proxy today for the director nominees who are aligned with their interests and are committed to the future success of the company.

  • Business Wire

    Leading Independent Proxy Advisors Recommend Aurinia Shareholders Vote the YELLOW Proxy Card FOR All of Aurinia’s Director Nominees

    Leading independent proxy advisory firms Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”) have recommended shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) vote the YELLOW proxy card in support of ALL of the Company’s nominees in advance of the upcoming Annual General Meeting of Shareholders (the “AGM”) to be held on Wednesday, June 26, 2019. Shareholders of record as of May 9, 2019 must submit their YELLOW proxy by 10:00 AM Mountain Time on Monday, June 24, 2019.

  • Business Wire

    ILJIN SNT Files Investor Presentation, Urging Aurinia Shareholders to Correct Governance Failures and Director Conflicts

    ILJIN SNT Co., Ltd. (“ILJIN”), a founding shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH, TSX: AUP) (“Aurinia” or the “Corporation”), which together with certain affiliates holds an approximate 14% ownership interest in Aurinia, today filed an investor presentation on SEDAR in connection with the Corporation’s upcoming Annual General Meeting of Shareholders to be held on Wednesday, June 26, 2019. The investor presentation is also available at www.AHealthierAurinia.com.

  • ILJIN SNT Sends Letter to Shareholders of Aurinia Highlighting Governance Failures and Director Conflicts and Responding to Misleading Information
    Business Wire

    ILJIN SNT Sends Letter to Shareholders of Aurinia Highlighting Governance Failures and Director Conflicts and Responding to Misleading Information

    ILJIN SNT Co., Ltd. (“ILJIN”) today sent a letter to shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (“Aurinia” or the “Corporation”), highlighting the governance failures and director conflicts under the current board of directors, correcting misleading information disseminated to shareholders by Aurinia on June 7, 2019 and urging shareholders to vote their GREEN proxy or GREEN VIF to strengthen the board. ILJIN, a founding shareholder of Aurinia which together with certain affiliates holds an approximately 14% ownership interest in Aurinia, is seeking support for three exceptional nominees for election as directors at the annual meeting: Dr. Robert Foster, Mr. Soon-Yub (Samuel) Kwon and Dr. Myeong-Hee Yu.

  • Business Wire

    Aurinia Issues Letter to Shareholders

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today sent a letter to shareholders in connection with the Company’s upcoming Annual General Meeting of Shareholders (“AGM”) to be held on Wednesday, June 26, 2019. Shareholders of record as of May 9, 2019 must submit their YELLOW proxy by 10:00 AM Mountain Time on Monday, June 24, 2019.

  • Business Wire

    Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences

    Aurinia Pharmaceuticals Inc. today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the fol

  • Business Wire

    Largest Shareholder of Aurinia Pharmaceuticals, ILJIN SNT, Files Proxy Circular and Issues Letter to Fellow Shareholders

    ILJIN SNT Co., Ltd. (“ILJIN”) today announced that it has filed an information circular (the "Circular") and letter to shareholders in connection with the upcoming Annual General Meeting of Shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH, TSX: AUP) (“Aurinia” or the “Corporation”) to be held on Wednesday, June 26, 2019. ILJIN, a founding shareholder of Aurinia which together with certain affiliates holds an approximately 14% ownership interest in Aurinia, is seeking support for three exceptional nominees for election as directors at the annual meeting: Dr. Robert Foster, Mr. Soon-Yub (Samuel) Kwon and Dr. Myeong-Hee Yu.

  • Business Wire

    Aurinia Pharmaceuticals Announces Upcoming Annual General Meeting of Shareholders

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), today filed its Notice of Meeting and Management Information Circular. Aurinia plans to host its upcoming Annual General Meeting of Shareholders (“AGM”) at 10:00 a.m. MT on Wednesday, June 26, 2019, at the Westin Calgary, 320 4th Ave SW in Calgary, Alberta. The Company also issued a letter to shareholders in response to the receipt of an advance notice of nominees from a minority shareholder who intends to nominate four alternate directors.

  • Business Wire

    Aurinia Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference

    Aurinia Pharmaceuticals Inc. today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 6:30am PT in New York, NY.

  • Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss
    Zacks

    Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss

    Aurinia (AUPH) delivered earnings and revenue surprises of 0.00% and 0.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    Aurinia: 1Q Earnings Snapshot

    The Victoria, British Columbia-based company said it had a loss of 14 cents per share. Losses, adjusted for non-recurring gains, were 16 cents per share. The results matched Wall Street expectations. The ...

  • Business Wire

    Aurinia Reports First Quarter 2019 Financial Results and Recent Operational Highlights

    - Conference call and webcast to be hosted today at 4:30pm EDT -

  • Business Wire

    Aurinia Recognizes World Lupus Day and Lupus Awareness Month with Activities Focused on Raising Awareness for Lupus Nephritis

    In recognition of Lupus Awareness Month and World Lupus Day, Aurinia Pharmaceuticals Inc. a late clinical-stage biopharmaceutical company with

  • Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
    Zacks

    Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.